58 results about "Corticosterone" patented technology

The invention discloses a probiotic with the depression improving effect and a microecological preparation and application thereof, and is characterized in that the probiotic comprises lactobacillus mucus PC17 with the preservation number of CGMCC No.33866, the active ingredients of the lactobacillus microecological preparation comprise thalli of the lactobacillus mucus PC17, and a preparation method of the microecological preparation comprises the following steps: adding the lactobacillus mucus PC17 into the lactobacillus mucus PC17, uniformly mixing the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17 and the lactobacillus mucus PC17 The lactic acid bacteria are inoculated into a fermentation culture medium according to a volume ratio of 1-5% to prepare the lactic acid bacteria microecological preparation, can be used for preparing antidepressant drugs, and has the advantages of being capable of promoting RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reducing the levels of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and corticotropin in serum, and improving the antidepressant activity of the antidepressant drugs. The levels of aminobutyric acid and brain-derived neurotrophic factors in serum are improved, and the depression-like behaviors of CUMS depression model mice are obviously improved.

The invention belongs to the technical field of protein, and relates to a peptide for promoting synthesis of a brain-derived neurotrophic factor (BDNF) as well as a preparation method and application of the peptide. The amino acid sequence of the peptide for promoting synthesis of the brain-derived neurotrophic factor BDNF is SGFSKHF, and the peptide has the main effects that damage of CORT (corticosterone) to PC12 cells can be protected, the peptide can be spontaneously combined with a TrkB receptor, the structure of a compound formed after combination is more stable, BDNF-TrkB-CREB pathway signal transduction can be activated, generation of the BDNF is promoted, and the effect of promoting synthesis of the brain-derived neurotrophic factor BDNF is achieved. Therefore, the occurrence and development of neurodegenerative diseases can be delayed.

The invention discloses an application of rhein in a medicine for inhibiting the activity of a glucocorticoid receptor, the rhein is associated with the glucocorticoid for the first time, and it is found that the rhein achieves the effect of inhibiting the activity of the glucocorticoid receptor by regulating and controlling the glucocorticoid receptor to convert co-activated molecules arginine and glutamic acid rich protein 1 (ARGLU1). Therefore, a basis can be provided for applying the rhein to the preparation of the medicine for inhibiting the activity of the glucocorticoid receptor, and the rhein can achieve an obvious improvement effect on anxiety caused by high-glucocorticoid including corticosterone. Rheinic acid can increase the browning degree of brown fat of mice and UCP1 expression and can induce fat browning, and in combination with mouse experiment results, it is shown that the rheinic acid increases energy consumption of organisms and reduces the body fat content, so that application of the rheinic acid in resisting obesity and improving metabolic syndromes caused by obesity has a prospect, and the rheinic acid can be used for preparing medicines for resisting obesity and improving metabolic syndromes caused by obesity. And more directions are provided for further development and application of the rhein.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The application belongs to the technical field of proteins, and particularly relates to a mood regulation peptide as well as a preparation method and application thereof. The amino acid sequence of the mood regulation peptide is TDLPSVVE, and the molecular weight is 859 Da. The mood regulation peptide can spontaneously combine with a StAR receptor, enhance the stability of the StAR receptor, and reduce the level of CORT (corticosterone) produced by Y1 cells, so as to play a mood regulation role.

The application belongs to the technical field of medicines, and specifically discloses an anti-depression m-hydroxybenzoic acid compound and a preparation method and application thereof; the m-hydroxybenzoic acid compound Hyperioxides A-F provided by the application has not been reported; the six compounds have good anti-depression effects, and further research shows that the compounds Hyperioxide A, Hyperioxide D, Hyperioxide E and Hyperioxide F have significant protective effects on SH-SY5Y cells induced by corticosterone, and are superior to positive drugs fluoxetine and Luoyoutei, and can be used for developing drugs for treating depression.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 neuron cells and hCMEC / D3 brain microvascular endothelial cells injured by oxygen-glucose deprivation (OGD) induction, and can resist the injury of PC12 cells induced by corticosterone (CORT) and MPP + , and effectively inhibit the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, and can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve and vascular units.

Provided are a Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease and a use thereof, and the Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease is named as Bifidobacterium longum subsp. infantis BI03 strain, with a deposit number of CGMCC No.24473 and deposit date of Mar. 7, 2022. The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.

The invention discloses application of Cacumen biotae-derived extracellular vesicles in preparation of drugs for treating anxiety, depression or insomnia. The EVs are separated and purified from cacumen biotae through a specific differential ultracentrifugation method, the EVs have a typical double-layer membrane structure, the average particle size is about 100 nm, about 1012 EVs can be extracted from each gram of cacumen biotae, and 62 volatile components are contained. Cacumen biotae EVs can be taken by PC12 cells, and corticosterone-induced neuron damage can be relieved; for chronic constraint stress model mice, anxiety behaviors and spatial learning and memory disorders can be improved, and central nervous inflammation can be inhibited; for chronic unpredictable mild stress model mice, the weight, the sucrose preference rate and the cognitive ability can be recovered, and the levels of 5-hydroxytryptamine and gamma-aminobutyric acid are increased; and for 4-chloro-DL-phenylalanine induced insomnia model mice, the sleep condition can be improved, the neurotransmitter level can be recovered, and the effect is equivalent to that of positive drugs such as citalopram, fluoxetine, diazepam and the like.

The application discloses application of prostaglandin A2 in preparation of a medicine for treating anxiety and the medicine, belongs to the technical field of biological medicine, and particularly relates to application of prostaglandin A2 in preparation of a medicine for treating anxiety. The application proves that prostaglandin A2 can exert a multi-target anti-anxiety effect from the aspects of overall behavior, cell function, neural loop structure and molecular level through a chronic restraint stress (CRS) mouse model, a PC12 cell model damaged by corticosterone (CORT) and multi-level molecular, loop and behavior analysis. Prostaglandin A2 can treat anxiety by improving anxiety-like behavior and reversing behavior phenotype damage.

The invention belongs to the technical field of medicines, and particularly discloses a novel tricyclic alpha acid compound as well as a preparation method and application thereof. According to the present invention, the novel tricyclic alpha acid compounds (+ / -)-Humulunes M-O and (-)-Garcinielliptone HE have not been reported at present; the compound has a remarkable protection effect on HT22 cells induced by corticosterone and SH-SY5Y cells induced by LPS (Lipopolysaccharide), and can be used for developing medicines for treating depression.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The invention relates to application of tetrahydrocortisol in preparation of a product for preventing and treating symptoms related to white hair. According to the application, corticosterone downstream metabolites are systematically evaluated through an in-vitro mouse whisker hair follicle model, and tetrahydrocortisol is found to play an important role in hair follicle microenvironment homeostasis, can remarkably improve hair pigment deficiency of stress-induced white hair mice, and is a new hormone with an extremely remarkable white hair improving effect.

The invention provides an essential oil composition for relieving depressive symptoms and a preparation method and application thereof, and belongs to the technical field of essential oil compositions. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 1-9 parts of perilla frutescens, 1-9 parts of rhizoma cyperi, 1-9 parts of pericarpium citri reticulatae and 1-9 parts of liquorice. The essential oil composition provided by the invention has a kidney channel protection effect, can reduce the rising corticosterone level in the body, alleviates the neuroendocrine dyscrasia related to depression by adjusting the hypothalamus-pituitary-adrenal axis (HPA axis) function, and can improve the appetite and metabolic state of the body at the same time.

The invention discloses application of a ganoderma lucidum extract in preparation of a product for improving skin problems, bidirectional regulation of skin homeostasis is realized through a dual-action mechanism, on one hand, conversion of corticosterone to cortisol is inhibited, and on the other hand, the skin homeostasis is inhibited; the problems of skin barrier injury, skin basement membrane injury, excessive sebum secretion, accelerated aging and the like caused by excessive cortisol are relieved; on the other hand, by inhibiting differentiation of macrophages induced by noradrenaline to inflammation phenotypes, the cortisol level is reduced, meanwhile, the skin inflammation response excited by early pressure is effectively controlled, and bidirectional regulation of skin homeostasis is achieved.

The invention belongs to the technical field of protein, and particularly relates to an emotion regulating peptide as well as a preparation method and application thereof. The amino acid sequence of the emotion regulating peptide is TDLPSVVE, and the molecular weight of the emotion regulating peptide is 859Da. The emotion regulating peptide can be spontaneously combined with a StAR receptor, the stability of the StAR receptor is enhanced, the level of CORT (corticosterone) generated by Y1 cells is reduced, and therefore the emotion regulating effect is achieved.

The application discloses a kind of medium chain inulin and its preparation method and application, belong to plant extraction technical field.The unique inulin structure and chain length disclosed in the application remodel intestinal microbiome and metabolome, especially selectively regulate key microorganisms such as coprococcus, bifidobacterium, parabacteroides, Clostridium_sensu_stricto_1 and Akkermansia, and metabolites such as nicotinamide, taurocholic acid, aldosterone, corticosterone, 2-(1H-indole-3-yl)acetic acid, 5-hydroxy-L-tryptophan, 5alpha-DHT and maltose, promote the improvement of host obesity and overall health status.The core microorganisms and metabolites identified by the technical scheme represent potential therapeutic targets for preventing or treating obesity and related metabolic symptoms.These findings support the development of inulin-based nutritional strategies to effectively manage weight by regulating specific microbiota and metabolome.

This invention discloses the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders and the related pharmaceutical formulation. It belongs to the field of biomedical technology, and specifically relates to the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders. Through chronic restraint stress (CRS) mouse models, corticosterone-induced (CORT)-damaged PC12 cell models, and multi-level molecular, circuit, and behavioral analyses, this invention demonstrates that prostaglandin A2 can exert multi-target anti-anxiety effects at the levels of overall behavior, cellular function, neural circuit structure, and molecularity. Prostaglandin A2 can treat anxiety disorders by improving anxiety-like behaviors and reversing behavioral phenotypic damage.

Use of bellidifolin (BEL) and / or a BEL-containing extract in preparation of an antidepressant product is provided, belonging to the technical field of medicine. The BEL or BEL-containing extract as an active ingredient can significantly improve a depressive behavior of mice, regulate concentrations of 5-hydroxytryptamine (HT) and corticosterone (CORT), protect nerve cells, and improve synaptic plasticity. Moreover, the BEL or BEL-containing extract can penetrate the blood-brain barrier (BBB) and has a significant effect on improving and treating depression. In addition, a method for preparing the BEL-containing extract has the advantages of simple operation, low cost, and desirable repeatability and stability. BEL in the extract has a concentration of up to 1.0% to 95.0%. After purifying the BEL-containing extract, the BEL has a high purity of up to 95.0% to 99.9%, and is easy to realize industrial production during the preparation.

The present invention provides compounds of Formula (I) or salts thereof: (Formula (I)) wherein X, L, V, R1, R2, R3 and R4 are as defined herein. The claimed compounds inhibit the enzyme type 2 11-hydroxysteroid dehydrogenase (11-HSD2) and thus stimulate potassium excretion by preventing cortisol from being oxidized to corticosterone and thus making it occupy the mineralocorticoid receptor, and are useful in the treatment of hyperkalemia. # imgabs0 #

CED-based methods, products and compositions for treating glioblastoma with anti-inflammatory therapeutics and chemotherapeutics without decreasing brain corticosterone compared to systemic delivery of dexamethasone, and not causing splenal atrophy and / or adrenal atrophy.

The present invention belongs to the field of natural medicines and chemical medicines for treating and preventing depression, and specifically discloses an iridoid glycoside compound, a preparation method thereof, and use of the iridoid glycoside compound in preparing antidepressant drugs. The iridoid glycoside compound extracted from the soft-branched yellow cicada has a structure selected from allamanoid C, allamanoid E, and allamanoid H, has a novel chemical structure, and has low toxicity to normal cells. Allamanoid C, allamanoid E, and allamanoid H exhibit significant neuroprotective effects on HT22 cell damage induced by corticosterone at low concentrations, and their activity is stronger than that of the positive control drug fluoxetine hydrochloride. Allamanoid C, allamanoid E, and allamanoid H have significant antidepressant effects on mouse despair depression models (tail suspension model and forced swim model), and therefore allamanoid C, allamanoid E, and allamanoid H can be used to prepare antidepressant drugs.

The invention discloses a construction method and application of a dog depression model. According to the method, the problems of dog allergy and fever in the modeling process are solved by injecting corticosterone through stepped increasing administration, and the dog depression model is successfully constructed for the first time. A large number of experiments prove that the dog depression model established by the invention successfully simulates the core phenotypes of human depression, such as pleasant sensation deficiency, low emotion, reduced interest and the like, and the major depression phenotype self-disability behavior appears for the first time. The method is simple, the molding period is greatly shortened, the success rate is increased to 80%, drug screening and pharmacology and toxicology synchronous research are supported, and the drug research and development cost is reduced. According to the invention, the problems of low clinical depression correlation and long non-human primate large animal modeling period of the existing mouse model are solved, and a standardized large animal platform with high prediction value is provided for research and development of antidepressant drugs.

The invention relates to the field of biological medicine, and discloses application of cycloastragenol in preparation of a medicine for treating lung adenocarcinoma combined anxiety depression. According to the application, cycloastragenol is found to relieve anxiety and depression symptoms by adjusting the level of corticosterone and other stress hormones; the anti-tumor immune response is enhanced by inhibiting the depletion of CD8 + T cells; and the anti-tumor capability of the CD8 + T cells is recovered by inhibiting the expression of Fabp5, so that a new idea and a potential drug choice are provided for clinical treatment of lung adenocarcinoma combined anxiety depression.

The application discloses a probiotic with the function of improving depression and a microecological preparation and application thereof, and has the characteristics that the probiotic comprises fermented Lactobacillus muci-deprounc PC17 with the preservation number of CGMCC No.33866; the active ingredient of the lactic acid bacteria microecological preparation comprises the bacterial body of the fermented Lactobacillus muci-deprounc PC17; the microecological preparation is prepared by inoculating the fermented Lactobacillus muci-deprounc PC17 into a fermentation culture medium at a proportion of 1-5% in volume ratio to prepare the lactic acid bacteria microecological preparation; and the lactic acid bacteria microecological preparation can be used to prepare an antidepressant drug, has the advantages that the lactic acid bacteria microecological preparation can promote RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reduce the levels of interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and adrenocorticotropic hormone in serum, improve the levels of butyric acid and brain-derived neurotrophic factor in serum, and obviously improve the depression-like behavior of CUMS depression model mice.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The invention relates to application of cannabidiol in preparation of a medicine for adjuvant therapy of hyperthyroidism, and belongs to the technical field of biological medicine. The invention aims to provide novel medical application of cannabidiol, namely application of cannabidiol in preparation of a medicine for adjuvant therapy of hyperthyroidism. Animal model in-vivo experiments prove that cannabidiol has a sedative effect on hyperthyroidism mice, can inhibit hyperactivity caused by hyperthyroidism and effectively relieve symptoms such as easy excitation, dysphoria and insomnia, is beneficial to emotion stabilization and creates favorable conditions for treatment of hyperthyroidism. Cell in-vitro experiments prove that cannabidiol can effectively block a stress signal channel triggered by corticosterone, relieve the stress reaction degree of liver cells, relieve the liver burden and promote liver function recovery, and a new intervention thought is provided for adjuvant therapy of hyperthyroidism liver injury.

The invention discloses an application of parabacteroides gore outer membrane vesicles in preparation of drugs for neuroprotection and / or anxiety disorder improvement. Researches show that the parabacteroides gore outer membrane vesicles can effectively antagonize corticosterone-induced nerve cell injury, can relieve anxiety-like behaviors of chronic constraint stress mice, and have good neuroprotection and anxiety-resistant activity. The invention provides a new drug choice for clinically treating nerve injury and relieving anxiety disorder, and has a wide application prospect in the aspect of treating nervous system diseases.

The invention relates to the technical field of traditional Chinese medicines, relates to a new application of a traditional Chinese medicine composition, and in particular relates to an application of the traditional Chinese medicine composition in preparing a medicine for preventing and / or treating depression. The traditional Chinese medicine composition is prepared from cassia twig, white peony root, honey-fried licorice root, ginger, jujube, ginseng, Chinese angelica, salted morinda officinalis and dwarf lilyturf tuber. The traditional Chinese medicine composition provided by the invention can obviously increase the body weight and social interaction index of a social contusion depression model mouse and reduce the corticosterone content in serum; and the total movement distance and the central region retention time of an open field experiment in a chronic mild stress rat depression model are obviously increased, the content of 5-HT in plasma is increased, and a good treatment effect on depression is achieved.